ALX Oncology Holdings Inc. (ALXO) is a Healthcare stock trading at $1.54 (as of 2026-06-18), with a market capitalization of $224.72M and a trailing P/E of -1.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
ALX Oncology Holdings Inc. develops immuno-oncology therapies for cancer patients. Its lead candidate, ALX148, is a CD47-blocking therapeutic in Phase 1b/2 for myelodysplastic syndromes and in trials for acute myeloid leukemia, non-Hodgkin’s lymphoma, and several solid tumors; it also has a preclinical program including ALTA-002, a SIRPa TRAAC.